AcelRX Pharmaceuticals Stock Price - ACRX

0.00
-1.49 (-100.00%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
AcelRX Pharmaceuticals Inc ACRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 1.49 0.00 0.00 0.00 1.49 19:00:00
Bid Price Ask Price Spread Spread % News
1.50 1.53 0.03 1.96% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

AcelRX Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 118.56M 79.57M $ -47.15M -0.81 - 77.58M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 9.00 2.50%

more financials information »

AcelRX Pharmaceuticals News

Loading Messages....

Latest ACRX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ACRX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.691.711.491.57857,905-0.20-11.83%
1 Month1.771.821.491.67630,940-0.28-15.82%
3 Months1.772.501.492.00822,383-0.28-15.82%
6 Months2.352.801.492.05815,866-0.86-36.6%
1 Year3.224.091.492.761,241,551-1.73-53.73%
3 Years3.105.751.493.081,291,457-1.61-51.94%
5 Years8.099.321.493.23943,665-6.60-81.58%

AcelRX Pharmaceuticals Description

AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The company's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The company has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet) known as DZUVEO in Europe indicated for the management of acute pain, severe enough to require an opioid analgesic for adult patients and one product candidate, Zalviso (sufentanil sublingual tablet system, SST system being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.